By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Synageva BioPharma 

Corporate Offices
128 Spring Street, Suite 520
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-890-1111 Fax: 781-890-1114


Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.

Key Statistics

Ownership: Public

Web Site: Synageva BioPharma
Symbol: GEVA

Company News
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015 7:31:32 AM
Synageva BioPharma (GEVA) Announces Pricing Of Public Offering Of Common Stock 1/7/2015 7:46:16 AM
Synageva BioPharma (GEVA) Announces A 2.5 Million Share Proposed Public Offering Of Its Common Stock 1/6/2015 7:19:04 AM
Synageva BioPharma (GEVA) Announces New Pipeline Programs And Other Company Progress 1/5/2015 7:20:14 AM
Synageva BioPharma (GEVA) Announces Sebelipase Alfa Marketing Authorization Application Validated By The European Medicines Agency 12/23/2014 10:29:22 AM
Synageva BioPharma (GEVA) To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12, 2015 at 9:00 a.m. PST 12/17/2014 9:56:47 AM
Synageva BioPharma (GEVA) Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB 12/15/2014 7:39:13 AM
Synageva BioPharma (GEVA) Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa And Submits Marketing Authorization Application To European Medicines Agency 12/2/2014 10:40:18 AM
Synageva BioPharma (GEVA) Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The American Association for Study of Liver Diseases Meeting 11/11/2014 7:20:06 AM
Synageva BioPharma (GEVA) Reports Third Quarter 2014 Financial Results 10/31/2014 7:38:01 AM